Rel1A binding inhibitor, process for producing the same and utilization thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 24, 2003
Grant Date -
N/A
app pub date -
Jun 4, 2001
filing date -
Dec 3, 1998
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Human ReIA-associated inhibitor (RAI) comprises 351 amino acids and is capable of binding to p65, a subunit of the transcription factor NF.kappa.B. A process for producing RAI, a cDNA encoding it, a fragment capable of hybridizing selectively to the cDNA sequence, a plasmid for expression and duplication comprising the cDNA, a host cell transformed with the plasmid, an antibody against the polypeptide, a pharmaceutical composition comprising the polypeptide or the antibody against it and a method for diagnosis of diseases using the antibody against the RAI are disclosed.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully